Shadid Anthony, Hok Kathryn D, Domozhirov Aleksey Y, Weng-Mills Tingting, Doursout Marie-Françoise, Banda Nirmal K, Restrepo Marcos I, Shivshankar Pooja
Center for Metabolic and Degenerative Diseases, The Brown Foundation Institute of Molecular Medicine for Prevention of Human Diseases, UTHealth-McGovern Medical School, Houston, TX 77030, USA.
Department of Biochemistry and Molecular Biology, UTHealth-McGovern Medical School, Houston, TX 77030, USA.
Immune Netw. 2025 Aug 20;25(4):e32. doi: 10.4110/in.2025.25.e32. eCollection 2025 Aug.
Complement anaphylatoxins C3a and C5a are potent immunomodulators whose impact extends well beyond their traditional roles in innate immunity. Acting through G protein-coupled receptors C3aR, C5aR1, and C5aR2, these peptides take part in coordinating immune cell recruitment, vascular tone, and tissue remodeling. Yet their functions are deeply context-dependent: while they play essential roles in microbial clearance and immune coordination, their overactivation contributes to immunopathology in a wide range of diseases. The anaphylatoxins play key roles in early pathogen containment but can also drive cytokine storm and tissue damage, as in coronavirus disease 2019 (COVID-19) and bacterial sepsis. In autoimmune conditions, the anaphylatoxins promote leukocyte infiltration and complement-mediated tissue injury. In chronic diseases, they contribute to fibrosis in diabetic kidney disease and idiopathic pulmonary fibrosis, and anaphylatoxins disrupt neurovascular integrity in neurodegenerative diseases. In cancer, C3a and C5a shape the tumor microenvironment by facilitating immune evasion, angiogenesis, and metastasis. As complement-targeted therapies gain momentum in clinical settings-particularly in the treatment of genetic disorders, such as paroxysmal nocturnal hemoglobinuria, more recently COVID-19, and cancer-a deeper mechanistic understanding of C3a and C5a signaling is imperative as we advance closer toward precision medicine, and this review aims to inform future approaches for therapeutic complement modulation.
补体过敏毒素C3a和C5a是强大的免疫调节剂,其影响远远超出了它们在固有免疫中的传统作用。这些肽通过G蛋白偶联受体C3aR、C5aR1和C5aR2发挥作用,参与协调免疫细胞募集、血管张力和组织重塑。然而,它们的功能在很大程度上取决于具体情况:虽然它们在微生物清除和免疫协调中发挥着重要作用,但它们的过度激活会导致多种疾病的免疫病理。过敏毒素在早期病原体控制中起关键作用,但也会引发细胞因子风暴和组织损伤,如在2019冠状病毒病(COVID-19)和细菌性败血症中。在自身免疫性疾病中,过敏毒素促进白细胞浸润和补体介导的组织损伤。在慢性疾病中,它们会导致糖尿病肾病和特发性肺纤维化中的纤维化,并且过敏毒素会破坏神经退行性疾病中的神经血管完整性。在癌症中,C3a和C5a通过促进免疫逃逸、血管生成和转移来塑造肿瘤微环境。随着补体靶向疗法在临床环境中获得发展势头,特别是在治疗阵发性夜间血红蛋白尿等遗传性疾病、最近的COVID-19和癌症方面,随着我们向精准医学迈进,对C3a和C5a信号传导进行更深入的机制理解势在必行,本综述旨在为未来治疗性补体调节方法提供参考。